HCP resources

AkebiaCares connects healthcare providers (HCPs) and patients to resources that can help patients access and stay on Akebia medication.

Effective December 31, 2024, the AkebiaCares Free Drug Program will be discontinued. Patients currently enrolled in the program will be eligible to receive medication through the end of 2024.

Due to CMS regulatory changes that will take into effect in 2025, your dialysis provider will be responsible for reimbursing oral-only medications.

For more information, please visit www.cms.gov .

Beginning January 1, 2025, the Centers for Medicare & Medicaid Services (CMS) is incorporating phosphate binders into the End-Stage Renal Disease (ESRD) Prospective Payment System (PPS). Separate payment will no longer be provided. CMS will pay for these drugs under the Transitional Drug Add-on Payment Adjustment (TDAPA).

For more information, please visit www.cms.gov .

TDAPA is a payment adjustment under the End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) for certain new renal dialysis drugs and biological products.

TDAPA helps ESRD facilities to incorporate certain new drugs and biological products and make appropriate changes in their businesses to adopt such products.

TDAPA provides additional payments for such associated costs and promotes competition among the products within the ESRD PPS functional categories, while also focusing Medicare resources on products that are innovative.

For more information, go to www.cms.gov .

We encourage you to talk to your clinical health decision leader at your Dialysis Organization to what the formulary status will look like in 2025 and how your patients can access the appropriate medication for them.